A pioneering eye injection treatment has restored vision in patients with hypotony, a rare condition where eyeball pressure drops dangerously low, causing the eye to collapse inward. Medical specialists at Moorfields hospital in London have successfully applied this groundbreaking approach to prevent blindness in affected individuals. The pilot study demonstrated that seven of eight patients responded positively to this innovative therapy, marking a significant advancement in ophthalmology.
Nicki Guy, aged 47, became the first patient to receive this experimental treatment. Her vision deteriorated starting in 2017 following her son’s birth, when her right eye began failing due to hypotony. Traditional approaches using silicone oil provided minimal relief, as the substance obscured sight despite restoring eye shape. When her left eye subsequently developed the same condition, she sought alternative solutions with unwavering determination.
Hypotony develops when internal eye pressure becomes abnormally low, potentially resulting from poor fluid production, trauma, inflammation, surgery complications, or medication side effects. Without intervention, patients face inevitable vision loss. Previous treatment methods relied on steroids and silicone oil to restore eye volume, but these approaches carried toxicity concerns and failed to significantly improve vision due to optical clarity issues.
The Moorfields team adopted an innovative strategy using hydroxypropyl methylcellulose, a transparent water-based gel already utilized in certain eye surgeries. Rather than employing it as a temporary surgical aid, they developed a novel therapy involving regular injections into the eye’s main chamber. This approach restores proper eye pressure while maintaining optical clarity, allowing light to reach vision cells effectively.
Nicki now reads nearly all letters on standard vision charts, falling just below the legal driving threshold—a dramatic improvement from her previous near-blindness requiring magnification devices. She expresses profound gratitude for this transformation, stating the treatment has fundamentally changed her life and restored her ability to witness her child’s development. The therapeutic protocol requires injections administered every three to four weeks over approximately ten months.
Thirty-five patients have received treatment thus far, with results from the initial eight cases published in the British Journal of Ophthalmology. Mr Harry Petrushkin, her treating physician, emphasizes that hundreds or thousands of UK residents annually could potentially benefit from this intervention, provided their retinal cells remain functional. He describes the unexpected success as remarkable, noting that patients expected to lose sight in both eyes are now living normal lives.
